(CRBG) Corebridge Financial - Overview
Stock: Annuities, Life Insurance, Retirement Plans, Institutional Products
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.04% |
| Yield on Cost 5y | 5.85% |
| Yield CAGR 5y | 27.79% |
| Payout Consistency | 76.8% |
| Payout Ratio | 27.6% |
| Risk 5d forecast | |
|---|---|
| Volatility | 38.8% |
| Relative Tail Risk | -0.94% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.02 |
| Alpha | -23.80 |
| Character TTM | |
|---|---|
| Beta | 1.415 |
| Beta Downside | 1.781 |
| Drawdowns 3y | |
|---|---|
| Max DD | 31.79% |
| CAGR/Max DD | 0.69 |
Description: CRBG Corebridge Financial December 19, 2025
Corebridge Financial, Inc. (NYSE: CRBG) delivers retirement and insurance solutions across four business lines: Individual Retirement (fixed, indexed, and variable annuities), Group Retirement (in-plan recordkeeping, flexible annuities, and advisory services), Life Insurance (term, whole, index universal, and guaranteed universal life), and Institutional Markets (stable-value wraps, pension-risk-transfer annuities, private-placement life and annuity products, and guaranteed investment contracts). The firm, originally SAFG Retirement Services, was founded in 1998 and is headquartered in Houston, Texas.
Key recent metrics: Q3 2024 reported a 7% YoY increase in annuity premium volume, driven by rising interest-rate spreads that make fixed-index products more attractive; the Life Insurance segment posted a combined ratio of 92.3%, indicating underwriting profitability despite a competitive market. Macro-level drivers include the aging U.S. population-projected to push the 65-plus cohort to 22% of the population by 2030-and the Fed’s policy cycle, which influences the pricing of fixed-income-linked annuities and stable-value wraps.
For a deeper dive into CRBG’s valuation nuances, consider exploring ValueRay’s analytical tools.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: 991.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA -0.16 > 1.0 |
| NWC/Revenue: 1939 % < 20% (prev 2579 %; Δ -640.7% < -1%) |
| CFO/TA 0.00 > 3% & CFO 1.62b > Net Income 991.0m |
| Net Debt (10.70b) to EBITDA (2.42b): 4.42 < 3 |
| Current Ratio: 6.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (540.6m) vs 12m ago -7.92% < -2% |
| Gross Margin: 80.35% > 18% (prev 0.79%; Δ 7956 % > 0.5%) |
| Asset Turnover: 0.71% > 50% (prev 0.64%; Δ 0.06% > 0%) |
| Interest Coverage Ratio: 3.50 > 6 (EBITDA TTM 2.42b / Interest Expense TTM 565.0m) |
Altman Z'' 1.08
| A: 0.14 (Total Current Assets 65.09b - Total Current Liabilities 9.36b) / Total Assets 411.29b |
| B: 0.04 (Retained Earnings 17.68b / Total Assets 411.29b) |
| C: 0.00 (EBIT TTM 1.98b / Avg Total Assets 405.36b) |
| D: 0.02 (Book Value of Equity 8.66b / Total Liabilities 396.97b) |
| Altman-Z'' Score: 1.08 = BB |
What is the price of CRBG shares?
Over the past week, the price has changed by +1.07%, over one month by +0.42%, over three months by +4.97% and over the past year by -3.34%.
Is CRBG a buy, sell or hold?
- StrongBuy: 6
- Buy: 5
- Hold: 2
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the CRBG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 37.7 | 21% |
| Analysts Target Price | 37.7 | 21% |
| ValueRay Target Price | 35.7 | 14.4% |
CRBG Fundamental Data Overview February 05, 2026
P/E Forward = 5.9559
P/S = 0.8283
P/B = 1.1602
Revenue TTM = 2.88b USD
EBIT TTM = 1.98b USD
EBITDA TTM = 2.42b USD
Long Term Debt = 11.02b USD (from longTermDebt, last quarter)
Short Term Debt = 9.36b USD (from shortTermDebt, last quarter)
Debt = 11.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.70b USD (from netDebt column, last quarter)
Enterprise Value = -38.27b USD (15.19b + Debt 11.02b - CCE 64.47b)
Interest Coverage Ratio = 3.50 (Ebit TTM 1.98b / Interest Expense TTM 565.0m)
EV/FCF = -23.64x (Enterprise Value -38.27b / FCF TTM 1.62b)
FCF Yield = -4.23% (FCF TTM 1.62b / Enterprise Value -38.27b)
FCF Margin = 56.31% (FCF TTM 1.62b / Revenue TTM 2.88b)
Net Margin = 34.47% (Net Income TTM 991.0m / Revenue TTM 2.88b)
Gross Margin = 80.35% ((Revenue TTM 2.88b - Cost of Revenue TTM 565.0m) / Revenue TTM)
Gross Margin QoQ = 81.35% (prev 81.41%)
Tobins Q-Ratio = -0.09 (set to none) (Enterprise Value -38.27b / Total Assets 411.29b)
Interest Expense / Debt = 1.23% (Interest Expense 135.0m / Debt 11.02b)
Taxrate = 21.41% (600.0m / 2.80b)
NOPAT = 1.55b (EBIT 1.98b * (1 - 21.41%))
Current Ratio = 6.96 (Total Current Assets 65.09b / Total Current Liabilities 9.36b)
Debt / Equity = 0.81 (Debt 11.02b / totalStockholderEquity, last quarter 13.54b)
Debt / EBITDA = 4.42 (Net Debt 10.70b / EBITDA 2.42b)
Debt / FCF = 6.61 (Net Debt 10.70b / FCF TTM 1.62b)
Total Stockholder Equity = 12.32b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.24% (Net Income 991.0m / Total Assets 411.29b)
RoE = 8.04% (Net Income TTM 991.0m / Total Stockholder Equity 12.32b)
RoCE = 8.48% (EBIT 1.98b / Capital Employed (Equity 12.32b + L.T.Debt 11.02b))
RoIC = 6.45% (NOPAT 1.55b / Invested Capital 24.09b)
WACC = 6.86% (E(15.19b)/V(26.20b) * Re(11.13%) + D(11.02b)/V(26.20b) * Rd(1.23%) * (1-Tc(0.21)))
Discount Rate = 11.13% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -7.59%
[DCF Debug] Terminal Value 83.45% ; FCFF base≈1.85b ; Y1≈2.02b ; Y5≈2.53b
Fair Price DCF = 90.96 (EV 56.58b - Net Debt 10.70b = Equity 45.88b / Shares 504.4m; r=6.86% [WACC]; 5y FCF grow 10.00% → 2.90% )
EPS Correlation: -30.32 | EPS CAGR: -65.20% | SUE: -4.0 | # QB: 0
Revenue Correlation: -21.89 | Revenue CAGR: -45.28% | SUE: -0.68 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.20 | Chg30d=-0.020 | Revisions Net=-6 | Analysts=11
EPS next Year (2026-12-31): EPS=5.23 | Chg30d=-0.120 | Revisions Net=-8 | Growth EPS=+19.6% | Growth Revenue=+6.3%